ReCode Therapeutics Appoints Angèle Maki, Ph.D., as Senior Vice President of Business Development

Dr. Maki brings nearly 20 years of biotechnology and pharma business development expertise as Company rapidly advances its powerful LNP platform to deliver mRNA-based therapies

Menlo Park, Calif. and Dallas, Texas – August 16, 2021 – ReCode Therapeutics (the “Company”), a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced the appointment of Angèle Maki, Ph.D., as senior vice president, business development. Dr. Maki will help lead the company’s long-term business strategy, partnering, and corporate development. She joins ReCode from Eli Lilly and Company, where she served as vice president, venture science, corporate business development.

“Angèle is an accomplished business development leader with an exceptional track record in the life sciences industry and is a welcome addition to our fast-growing team at ReCode,” said David Lockhart, Ph.D., CEO and President, ReCode Therapeutics. “I am confident her unique expertise in business development and partnering with drug development companies will be a strong asset as we propel ReCode into the next stage of growth including advancement of our cutting-edge LNP platform and pipeline of genetic medicines for patients with life-limiting respiratory diseases.”

Dr. Maki is an accomplished business development executive with nearly 20 years of deal-making and corporate development experience at both small biotechnology and large pharmaceutical companies. Dr. Maki previously served as vice president, venture science, corporate business development at Eli Lilly, where she was responsible for setting strategy and sourcing innovative science and therapeutics for Lilly in the Bay Area. Prior to Lilly, she held business development leadership roles with increasing responsibility starting at Medarex, followed by BMS (which acquired Medarex), Genentech, 23andMe, and Merck & Co. During her career, she has successfully led diligence and negotiations on numerous in- and out-licensing transactions, from early-stage research technologies to clinical-stage assets. Dr. Maki earned a Ph.D. in biological chemistry from Stanford University, completed postdoctoral work in molecular biology at The Scripps Research Institute in La Jolla, California, and received a B.S. in chemistry from the University of Winnipeg in Canada.

About ReCode Therapeutics

ReCode Therapeutics is an integrated genetic medicines company developing disease-modifying therapeutics using its powerful LNP delivery technology to target organs and tissues beyond the liver. The Company’s pipeline includes lead programs for patients with life-limiting genetic respiratory diseases, including cystic fibrosis and primary ciliary dyskinesia. The Company is leveraging its proprietary LNP platform and nucleic acid technologies and utilizing systemic and direct delivery for mRNA-mediated replacement and gene editing/correction in target cells, including stem cells. For more information, visit www.recodetx.com and follow us on Twitter @ReCodeTx and LinkedIn.

Media Contact:
Will Zasadny
Canale Communications, Inc.
Will.zasadny@canalecomm.com
(619) 961-8848

Investor Contact:
Sarah McCabe
Stern Investor Relations
sarah.mcCabe@sternir.com
IR@recodetx.com